Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab

Efficacy and change of serum IL-6 levels in patients with rheumatoid arthritis treated with tocilizumab - Efficacy and serum IL-6 in RA treated with tocilizumab

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017947

Enrollment

Registered

2015-06-21

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with RA who met the 1987 revised criteria of ACR or the 2010 ACR/EULAR classification criteria. Patients with active RA who had been treated with at least one biologics.

Exclusion criteria

Exclusion criteria: Patients who corresponds to a contraindication of tocilizumab

Design outcomes

Primary

Measure	Time frame
Remission rate at 24 weeks. Change of serum IL-6 levels at 24 weeks and 52 weeks	—

Secondary

Measure	Time frame
Remission rate at 12 weeks and 52 weeks	—

Countries

Japan

Contacts

Public ContactYoshifumi Tada

Saga University Department of Rheumatology

taday@cc.saga-u.ac.jp0952-34-2367

Outcome results